- Home
- CSR vs GYRE Comparison
CSR vs GYRE Comparison
Compare CSR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- GYRE
- Stock Information
- Founded
- CSR 1970
- GYRE 2002
- Country
- CSR United States
- GYRE United States
- Employees
- CSR N/A
- GYRE N/A
- Industry
- CSR Real Estate Investment Trusts
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CSR Real Estate
- GYRE Health Care
- Exchange
- CSR Nasdaq
- GYRE Nasdaq
- Market Cap
- CSR 1.0B
- GYRE 1.1B
- IPO Year
- CSR N/A
- GYRE N/A
- Fundamental
- Price
- CSR $61.06
- GYRE $11.19
- Analyst Decision
- CSR Buy
- GYRE
- Analyst Count
- CSR 8
- GYRE 0
- Target Price
- CSR $71.57
- GYRE N/A
- AVG Volume (30 Days)
- CSR 81.6K
- GYRE 110.3K
- Earning Date
- CSR 02-18-2025
- GYRE 11-13-2024
- Dividend Yield
- CSR 4.93%
- GYRE N/A
- EPS Growth
- CSR N/A
- GYRE N/A
- EPS
- CSR N/A
- GYRE N/A
- Revenue
- CSR $258,642,000.00
- GYRE $105,033,000.00
- Revenue This Year
- CSR N/A
- GYRE $25.32
- Revenue Next Year
- CSR $3.47
- GYRE $12.95
- P/E Ratio
- CSR N/A
- GYRE N/A
- Revenue Growth
- CSR N/A
- GYRE N/A
- 52 Week Low
- CSR $20.10
- GYRE $8.26
- 52 Week High
- CSR $76.16
- GYRE $26.37
- Technical
- Relative Strength Index (RSI)
- CSR 35.40
- GYRE 51.52
- Support Level
- CSR $60.31
- GYRE $10.41
- Resistance Level
- CSR $62.83
- GYRE $11.36
- Average True Range (ATR)
- CSR 1.50
- GYRE 0.69
- MACD
- CSR 0.14
- GYRE 0.09
- Stochastic Oscillator
- CSR 25.40
- GYRE 60.22
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and they conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.